NuScience Peptides LLC — FDA Warning Letter, 2026-08-24: Unapproved New Drugs/Misbranded
Letter issued · posted to fda.gov .
Subject as published: Unapproved New Drugs/Misbranded
TL;DR
At a glance: **FDA Warning Letter | NuScience Peptides LLC | CDER | August 24, 2026** The FDA Center for Drug Evaluation and Research (CDER) issued a warning letter to NuScience Peptides LLC (Cornelius, NC) citing violations of the Federal Food, Drug, and Cosmetic Act regarding nine unapproved peptide products sold via nusciencepeptides.com, including GLP-2 Tirz Peptide, GLP-1 Sema Research Peptide, GLP-3 RT, Survodutide, Mazdutide, PT-141 Peptide, Tesamorelin products, and Bacteriostatic Water for Peptides. The FDA determined these products meet the definition of drugs under section 201(g)(1) based on website labeling indicating intended use for treating metabolic disorders, obesity, type 2 diabetes, and other conditions, and stated that injectable drug products pose particular public health risks as they bypass the body's natural defenses. The letter states that failure to address violations may result in seizure, injunction, or other regulatory action.
Argus analysis
# FDA Warning Letter Analysis: NuScience Peptides LLC
## Company and Findings
NuScience Peptides LLC, a North Carolina-based firm operated by Joseph and Ratsamy DeRosa, received a warning letter from the FDA's Center for Drug Evaluation and Research (CDER) on August 24, 2026. The agency conducted a website review in July 2026 and identified nine peptide products and bacteriostatic water being marketed without FDA approval. The products include GLP-2 Tirz, GLP-1 Semaglutide, GLP-3 Retatrutide, Survodutide, Mazdutide, PT-141 (Bremelanotide), Tesamorelin formulations, and bacteriostatic water for reconstitution. The FDA emphasized particular concern because these are injectable products that bypass the body's natural defenses against contamination and toxins.
## Regulatory Citations
The violations center on 21 CFR Section 201(g)(1), which defines drugs based on intended use—whether for diagnosis, cure, mitigation, treatment, prevention of disease, or affecting body structure or function. The warning cites sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act, which prohibit introducing unapproved new drugs into interstate commerce. Products are classified as "new drugs" under 21 CFR Section 201(p) because they are not generally recognized as safe and effective (GRASE) for their labeled uses. The FDA's evidence included website language describing metabolic effects, weight loss, diabetes applications, and clinical study outcomes—language demonstrating drug intent rather than research-only positioning.
## Response Timeline and Industry Monitoring
Companies typically have 15 business days to respond to warning letters, though the letter does not specify a deadline here. Compliance officers monitoring NuScience or similar peptide distributors should watch for: removal of disease-claim language from websites, cessation of product sales, submission of a citizen petition or advisory opinion request, or FDA enforcement action including product seizure or injunction. The public health emphasis on injectable products suggests increased FDA scrutiny of unregulated peptide markets generally.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
Unapproved-drug letters cite 21 USC 355 (NDA requirement) or 21 USC 331(d) (introduction into interstate commerce). FDA increasingly applies these provisions to homeopathic products, kratom, and certain compounded preparations.
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER NuScience Peptides LLC MARCS-CMS 733652 — August 24, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTED Product: Drugs Recipient: Recipient Name Joseph and Ratsamy DeRosa Recipient Title Managers NuScience Peptides LLC 20311 Chartwell Center Dr., Suite 212 Cornelius , NC 28031 United States info@nusciencepeptides.com Issuing Office: Center for Drug Evaluation and Research (CDER) United States August 24, 2026 WARNING LETTER Reference Number: 733652 To Joseph and Ratsamy DeRosa: This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of your website. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. These products are especially concerning from a public health perspective because injectable drug products can pose risks of serious harm to users. Injectable products are delivered directly into the body, sometimes directly into the bloodstream, and therefore, bypass some of the body’s key defenses against toxins and microorganisms that can lead to serious and life-threatening conditions. FDA Review Violations were identified and documented during a review of your website nusciencepeptides.com in July 2026. Based on our review, “GLP-2 Tirz Peptide,” “GLP-1 Sema Research Peptide,” “GLP-3 RT (Retatrutide) Research Peptide,” “Survodutide,” “Mazdutide,” “PT-141 Peptide (Bremelanotide),” “Tesamorelin Research Peptide,” “Tesamorelin Ipamorelin Blend,” and “Bacteriostatic water for Peptides (BAC Water)” are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). This review was conducted as part of FDA’s public health responsibility to protect the public from unsafe, ineffective, and poor-quality drugs. Violations of the Federal Food, Drug, and Cosmetic Act The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations. Unapproved New Drug Violations Based on a review of your website, “GLP-2 Tirz Peptide,” “GLP-1 Sema Research Peptide,” “GLP-3 RT (Retatrutide) Research Peptide,…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- Is the FDA warning letter to NuScience Peptides LLC publicly available?
- Yes. The full verbatim letter is published at fda.gov. Argus HQ links directly to the source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nuscience-peptides-llc-733652-08242026.
- What does a "critical" severity rating mean for this letter?
- Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
- What is the regulatory background for a Unapproved drug warning letter?
- Unapproved-drug letters cite 21 USC 355 (NDA requirement) or 21 USC 331(d) (introduction into interstate commerce). FDA increasingly applies these provisions to homeopathic products, kratom, and certain compounded preparations.
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). NuScience Peptides LLC — FDA Warning Letter, 2026-08-24: Unapproved New Drugs/Misbranded. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-nuscience-peptides-llc-2026-08-24-unapproved-drug
"NuScience Peptides LLC — FDA Warning Letter, 2026-08-24: Unapproved New Drugs/Misbranded." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-nuscience-peptides-llc-2026-08-24-unapproved-drug.
Argus HQ Research. "NuScience Peptides LLC — FDA Warning Letter, 2026-08-24: Unapproved New Drugs/Misbranded." Digital Empire Holdings LLC. Accessed September 2, 2026. https://argushq.ai/fda/warning-letter/fda-wl-nuscience-peptides-llc-2026-08-24-unapproved-drug.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_nuscience_peptides_llc_2026_08_24_unapproved_drug_2026,
title = {NuScience Peptides LLC — FDA Warning Letter, 2026-08-24: Unapproved New Drugs/Misbranded},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-nuscience-peptides-llc-2026-08-24-unapproved-drug},
note = {Accessed: September 2, 2026}
}